To further elucidate the profiles of the downstream molecules of the AXL axis, we investigated the combined efficacy of osimertinib with molecular-targeting drugs, such as those targeting AKT, MEK, or NFκB, in EGFR-mutated NSCLC cells with a high level of AXL. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.